Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator

por Wang, Kun, Yao, Xueting, Zhang, Miao, Liu, Dongyang, Gao, Yuying, Sahasranaman, Srikumar, Ou, Ying C.
Publicado 2021

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

por Zhang, Heather, Ou, Ying C., Su, Dan, Wang, Fan, Wang, Lai, Sahasranaman, Srikumar, Tang, Zhiyu
Publicado 2021

Investigations of methylmercury-induced alterations in neurogenesis.

por Faustman, Elaine M, Ponce, Rafael A, Ou, Ying C, Mendoza, Ma Aileen C, Lewandowski, Thomas, Kavanagh, Terrance
Publicado 2002

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

por Ou, Ying C., Liu, Lucy, Tariq, Bilal, Wang, Kun, Jindal, Ashutosh, Tang, Zhiyu, Gao, Yuying, Sahasranaman, Srikumar
Publicado 2021

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP

por Ou, Ying C., Tang, Zhiyu, Novotny, William, Tawashi, Manal, Li, Ta‐Kai, Coleman, Hugh A., Sahasranaman, Srikumar
Publicado 2021

No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects

por Mu, Song, Darpo, Borje, Tang, Zhiyu, Novotny, William, Tawashi, Manal, Xue, Hongqi, Willett, Michael, Lin, Leo, Sahasranaman, Sri, Ou, Ying C.
Publicado 2020

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-...

por Tam, Constantine, Shadman, Mazyar, Sharman, Jeff, Cull, Gavin, Phillips, Tycel, Trotman, Judith, Cohen, Aileen, Allewelt, Heather, Crescenzo, Rocco, Delarue, Richard, Zhang, Heather, Tariq, Bilal, Sahasranaman, Sri, Ou, Ying C, Flinn, Ian W
Publicado 2023